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Key Messages 
What is already known about this subject? 
 Involvement of the nervous system in SLE is well recognized but the frequency and outcomes 
have not been well documented in different stages of the disease. 
What does this study add? 
 All neuropsychiatric (NP) events were documented over a mean follow-up of 7.6 years in a 
large observational inception cohort study of SLE patients.   
 A multistate modelling approach was used to describe the frequency, attribution, association 
with health-related quality of life and clinical outcome of NP events. 
 Predictive probability models were derived to estimate the likelihood of changing NP states 
over the first 10 years of SLE. 
How might this impact on clinical practice or future developments? 
 Most NP events in SLE patients occur early in the disease course, have a negative impact on 
health-related quality of life and are attributed to SLE in 30% of cases. 
 Multistate modelling is well suited to the study of NPSLE and could serve as an outcome 
measure in clinical trials (e.g. comparing the rate of transition between NPSLE states for 
patients receiving active treatment and comparator) and long-term observational studies (e.g. 
duration of time spent in different NPSLE states over the course of study).   It also provides the 
basis for economic studies of health care costs in SLE patients with NP events, either 
attributed to SLE or non-SLE causes.  
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Abstract 
 
Objectives: Using a reversible multistate model, we prospectively examined neuropsychiatric (NP) 
events for attribution, outcome and association with health-related quality of life (HRQoL), in an 
international, inception cohort of SLE patients. 
Methods: Annual assessments for 19 NP events attributed to SLE and non-SLE causes, physician 
determination of outcome and patient HRQoL (SF-36 scores) were measured. Time-to-event analysis 
and multistate modelling examined the onset, recurrence and transition between NP states.  
Results: NP events occurred in 955/1,827 (52.3%) patients and 592/1910 (31.0%) unique events 
were attributed to SLE. In the first two years of follow-up the relative risk (95% CI) for SLE NP events 
was 6.16 (4.96, 7.66) and non-SLE events was 4.66 (4.01, 5.43) compared with thereafter. Patients 
without SLE NP events at initial assessment had a 74% probability of being event-free at 10 years. 
For non-SLE NP events the estimate was 48%. The majority of NP events resolved over 10 years but 
mortality was higher in patients with NP events attributed to SLE (16%) versus patients with no 
NPSLE events (6%) while the rate was comparable in patients with non-SLE NP events (7%) 
compared to patients with no non-SLE events (6%). Patients with NP events had lower SF-36 
summary scores compared to those without NP events and resolved NP states (p<0.001). 
Conclusions: NP events occur most frequently around the diagnosis of SLE. Although the majority of 
events resolve they are associated with reduced HRQoL and excess mortality. Multistate modelling is 
well suited for the assessment of NP events in SLE. 
 
Key words: Systemic lupus erythematosus, Multistate modeling, Neuropsychiatric 
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Nervous system disease in SLE consists of neurologic and psychiatric events, predominantly 
affecting the central nervous system(1). Neuropsychiatric (NP) events vary in frequency, complexity, 
time of onset, rates of resolution and recurrence. Approximately 30% of NP events are attributed to 
SLE(2, 3), although the rate varies between individual manifestations. Regardless of attribution, the 
majority of events are associated with lower self-reported health related quality of life (HRQoL)(2). 
 
There are few clinical trials to guide interventions in SLE patients with NP events.  Many 
observational studies are single centre experiences, frequently cross-sectional in design and utilize 
prevalent SLE cohorts. Longitudinal studies have not captured the bidirectional movement of patients 
between remissions and relapses of NP events, the duration in different NP states and likelihood of 
moving from one state to another over time. 
 
Multistate models(4) offer a convenient and flexible framework to characterize changes in NP disease 
and provide a dynamic representation of the disease in continuous time. They also estimate time 
spent in different states and probabilities of being in particular states following specified time periods. 
Such summary inferences are more informative than models that focus on single, often dichotomous, 
outcomes such as the time to a specific clinical event. In common with other time-to-event modelling, 
these inferences are based on all follow-up data, not simply on data from subsets of patients with a 
specific follow-up time.  
 
The current study utilized data from a large, prospective, international, disease inception cohort of 
SLE patients, who underwent annual assessment for NP events for up to 18 years. The overall 
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objective was to model, over time, patient status with respect to NP events, incorporating attribution 
and association with HRQoL. To capture dynamic change in NP events, we adopted a reversible 
multistate model characterized by transition rates between states. 
 
Patients and Methods 
Research study network: The study was conducted by the Systemic Lupus International 
Collaborating Clinics (SLICC)(5), a network of 52 investigators at 43 academic centres in 16 
countries. Recently diagnosed SLE patients were recruited from 31 SLICC sites in Europe, Asia, and 
North America. Data were collected per protocol at enrollment and annually ensuring data quality, 
management and security. The Nova Scotia Health Authority central zone Research Ethics Board 
and each of the participating centres‟ research ethics review boards approved the study. This 
research was planned without patient involvement. 
 
Patients: Enrollment was permitted up to 15 months following diagnosis of SLE, taken as when the 
revised ACR classification criteria(6) were first recognized. Lupus-related variables included the SLE 
Disease Activity Index 2000 (SLEDAI-2K)(7) and SLICC/ACR Damage Index (SDI)(8).  
 
Neuropsychiatric  events: NP events were characterized within an enrollment window (6 months 
prior to the diagnosis of SLE up to the enrollment date) using ACR case definitions for 19 NP 
syndromes(9). Patients were reassessed annually within a 6-month window using a detailed protocol 
to record information on 19 NP syndromes(9), presence of pre-specified non-SLE causes, results of 
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appropriate investigations, medications and outcomes. New NP events that had occurred since the 
last study assessment and status of previous NP events were determined at each assessment.  For 
recurring events within an assessment period, the date of the first episode was taken as the onset of 
the event. Additional details are provided in Supplementary file S1. 
 
Attribution of NP events: Factors considered in the attribution decision rules included: (i) temporal 
onset of NP event(s) in relation to the diagnosis of SLE; (ii) concurrent non-SLE factor(s), such as 
potential causes (“exclusions”) or contributing factors (“associations”) for each NP syndrome in the 
glossary for the ACR case definitions of NP events(9); and (iii) “common” NP events that are frequent 
in normal population controls as described by Ainiala et al(10). These include isolated headaches, 
anxiety, mild depression (mood disorders failing to meet criteria for “major depressive-like episodes”), 
mild cognitive impairment (deficits in less than three of the eight specified cognitive domains) and 
peripheral neuropathy without electrophysiological confirmation. Two attribution decision rules of 
different stringency (models A and B) were derived(11, 12).  
Attribution Model A (more stringent):  NP events attributed to SLE (i) had their onset within the 
enrollment window or subsequently and (ii) had no “exclusions” or “associations” and (iii) were not 
one of the NP events identified by Ainiala(10).  
Attribution Model B (less stringent): NP events attributed to SLE  (i) had their onset within 10 years 
of the diagnosis of SLE and were still present within the enrollment window, or occurred 
subsequently, and (ii) had no “exclusions” and (iii) were not one of the NP events identified by 
Ainiala(10). 
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All NP events attributed to SLE using model A were included in the NP events using model B. All 
other events were classified as a non-SLE NP event(13, 14).  
Outcome of NP events: Physician-generated 7-point Likert scale score at each follow-up 
assessment compared the change in NP events between onset and follow-up (1=patient demise, 
2=much worse, 3=worse, 4=no change, 5=improved, 6=much improved, 7=resolved)(15). Separately 
a patient-generated SF-36 questionnaire at each assessment provided eight subscale scores and 
mental (MCS) and physical (PCS) component summary scores(15, 16).  
 
Statistical analysis: Two multistate patient level models were examined (Figure 1), one for NP 
events attributed to SLE(model B) and the other for non-SLE events. Non-SLE events were ignored 
during modelling of SLE events and vice-versa. The four states were: 
1. No NP event ever. 
2. No current NP event but ≥1 in the past. State entry was the time of resolution of NP event(s). 
3. New/Ongoing NP event(s) with state entry at onset of NP event. 
4. Death 
Modelling assumed transitions occurred at any time, not just at assessments. Each site investigator 
provided the approximate dates for onset and resolution of NP events and precise dates for death.  
 
The time origin was 6 months before SLE diagnosis. The transition rate which characterizes the 
probability of changing from State 1 to State 3 in the first two years of follow-up was allowed to differ 
from the rate thereafter, as many events occurred in the earlier time period. All other transition rates 
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were assumed constant. Patients could move back and forth between States 2 (resolution of NP 
event) and 3 (new/ongoing NP event). The death rate was assumed to be the same from States 2 
and 3 but a separate rate was allowed from State 1 (no history of NP events). The model can be 
extended to allow explanatory variables to influence transition rates through a regression model on 
the logarithm of the transition rates. Maximum likelihood estimation of the model was implemented 
using the R(17) package „msm‟(18). SF-36 analyses used linear regression models with robust 
estimation via generalized estimating equations to adjust for correlation between multiple 
measurements for the same patient.  
 
Results 
Patients: 1,827 patients were recruited from October 1999 through December 2011, from the United 
States [n=540 (29.5%)], Europe [n=477 (26.1%)], Canada [n=418 (22.9%)], Mexico [n=223 (12.2%)] 
and Asia [n=169 (9.3%)]. At enrollment, the mean (SD) age was 35.1 (13.3) years, 88.8% of patients 
were female, with variable race/ethnicity (Caucasian 48.8%, African 16.8%, Hispanic 15.4%, Asian 
15.1% and other 3.9%) and the mean (SD) disease duration was 5.6 (4.2) months. The mean (SD) 
SLEDAI-2K was 5.3 (5.4) and SDI was 0.32 (0.74). Medications at enrollment included corticosteroids 
(70.3%), antimalarials (67.4%), immunosuppressants (40.1%), warfarin (5.4%), low dose aspirin 
(14.3%), antidepressants (10.1%), anticonvulsants (4.4%) and antipsychotic drugs (0.7%). The mean 
follow-up was 7.6±4.6 years, with1 to 19 assessments and ended in September 2017. One hundred 
patients died during the study. 
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Neuropsychiatric manifestations: NP events occurred in 955/1,827 (52.3%) patients and 493/1,827 
(27.0%) had ≥2 events. There were 1,910 unique NP events, encompassing all 19 NP syndromes(9), 
of which 1,749 (91.6%) involved the CNS and 161 (8.4%) the peripheral nervous system (PNS)(9). 
The NP events attributed to SLE varied from 17.9% (attribution model A) to 31.0% (attribution model 
B) and occurred in 13.5% (model A) to 21.2% (model B) of patients. Summary outcomes are provided 
in supplementary Tables S2 and S3 and detailed outcomes of individual manifestations may be found 
in previous publications (13, 14, 19-22). 
 
Transition rates between NP states, duration spent in each state and time to event analysis: 
The number of observed changes between NP states, for SLE and non-SLE events (Table 1) provide 
the basis for estimation of the multistate models.  
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Table 1: Observed changes between neuropsychiatric (NP) states and death for patients with SLE 
NP events and non-SLE NP events as determined using attribution model B. The lower part of the 
table shows the estimated average (95% CI) of total time (years) spent in neuropsychiatric (NP) and 
death* states over 10 years of follow-up after cohort entry. 
    ______________Transition to state__________________                                              
Transition from state No NP  Resolved NP      New/Ongoing NP 
*
Death 
SLE NP events   
No NP   12,539      -    387   61 
Resolved NP        -   1,561   60   18 
New/Ongoing NP       -      270   1,541   21 
 
Non-SLE NP events 
No NP   8,782       -            810   66 
Resolved NP       -   2,603   224   13  
New/Ongoing NP      -      645   3,294   21 
 
 
                                      ______________Estimated time (years) spent in state_______________ 
SLE NP      8.81   0.39      0.56      0.24 
(8.70, 8.92)   (0.33, 0.44)   (0.50, 0.64)   (0.21, 0.32) 
 
Non-SLE NP   7.32     0.92     1.46      0.30 
         (7.14, 7.48)   (0.84, 1.01)   (1.36, 1.58)   (0.24, 0.37) 
 
*
For the lower portion of Table 1, this refers to the average portion of the 10 year observation period 
that would be left after the death of a patient.  
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Some patients remained in the same NP state and others moved through one or more states. The 
table also summarizes the estimated average time spent in NP states or death state over 10 years of 
follow-up, assuming all patients were in the no NP event state initially. A composite of NP state 
occupancy and duration is illustrated in lasagna plots (Figure 2) where trajectories are displayed as a 
layered plot. For NP events attributed to SLE, the time spent in a new/ongoing NP state was lower 
(0.56) and the time spent in the no NP state was higher (8.81) than for NP events attributed to non-
SLE causes (1.46 for new/ongoing state and 7.32 for the no NP state).   
 
The time to onset of new and recurrent NP events is illustrated in Figure 3. For recurrent events the 
time origin was the resolution of any previous event. The rate of occurrence of first NP events was 
highest in the early years following the diagnosis of SLE, consistent with our modelling strategy of 
allowing a differential rate of events in the first two years of follow-up. Based on the multistate 
models, the estimated relative risk [95% confidence interval (CI)] in the first two years compared with 
the subsequent time period, was 6.16 (4.96, 7.66) for SLE NP events and 4.66 (4.01, 5.43) for non-
SLE events.  Recurrent SLE NP events occurred at a higher rate than first events with little difference 
in these rates for non-SLE events. 
 
Predictive probabilities for transitioning between NP states over time: The same multistate 
models provide estimates of the probability of having changed NP states or died over defined periods 
of time. The estimates for 10 years after entry into the no NP, resolved NP or new/ongoing NP event 
states are summarized in Table 2.  
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Table 2: Estimated predictive probabilities of the state a patient will be in after 10 years of follow-up 
for the three possible initial states, tabulated separately for SLE NP events and non-SLE NP events 
as determined using attribution model B. 
 
    __Estimated probability (95% CI) of being in NP state__                                             
Initial NP state    No NP    Resolved NP New/Ongoing NP Death 
No NP 
SLE NP events  0.74    0.13   0.07  0.06 
(0.72, 0.76)   (0.12 ,0.15)   (0.06, 0.09)  (0.05, 0.07) 
Non-SLE NP events 0.48    0.26   0.20  0.06 
(0.46, 0.51)   (0.24, 0.28)   (0.18, 0.21)  (0.06, 0.06) 
 
Resolved NP 
SLE NP events  -       0.72   0.13  0.16 
(0.68, 0.74)   (0.10, 0.16)  (0.12, 0.21) 
Non-SLE NP events -       0.67   0.26  0.07 
(0.64, 0.70)   (0.23, 0.29)  (0.05, 0.09) 
 
New/Ongoing NP 
SLE NP events  -        0.64   0.20  0.16 
(0.61, 0.68)   (0.17, 0.24)  (0.12, 0.21) 
Non-SLE NP events -        0.62   0.31  0.07 
(0.59, 0.65)   (0.28, 0.34)  (0.05, 0.09)
16 
 
For patients with no SLE NP event at cohort entry, there was an estimated 74% 
probability of remaining free of such events 10 years later. For NP events not attributed 
to SLE the estimate was 48%. For patients with resolved or new/ongoing NP events, the 
majority would be in a resolved NP state after 10 years. Estimates of having 
new/ongoing NP events after 10 years of follow-up were 13% and 20% for SLE NP 
events if the patient started follow-up in the resolved and new/ongoing states, 
respectively, and 26% and 31% for non-SLE NP events. Of note, the estimates of dying 
in a 10-year period were higher in patients with NP events (new/ongoing or resolved) 
attributed to SLE (16%) versus patients without SLE NP events (6%) with an estimated 
relative risk (RR, 95% CI) of death of 4.3 (2.7,6.7). Patients with non-SLE NP events 
had a lower death rate (7%), similar to patients with no non-SLE events (6%), with an 
estimated RR of 1.3 (0.8,2.0). After adjustment for age and post-secondary education, 
the RR associated with SLE NP events was slightly lower [RR=2.9 (1.6, 5.6)] but still 
substantially higher than that for non-SLE events [RR=1.3 (0.7,2.4)]. 
 
A comprehensive investigation of predictors for onset and resolution of NP events at the 
patient level is beyond the scope of this paper. Preliminary analyses in supplementary 
Tables S4 and S5 provide RR estimates, based on a multistate model using multivariate 
regression for predictors at cohort entry. The effects are assumed to be the same on the 
transitions to the NP event state from both the no NP event and the resolved state. The 
results suggest that males have higher rates of onset and resolution for both types of 
NP events. Asian race and post-secondary education are protective for SLE NP event 
onset and Asian and Hispanic race are associated with somewhat higher rates of 
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resolution for SLE events. Hispanic race and a higher age at diagnosis is protective for 
the onset of non-SLE NP events while all other races have a higher resolution rate for 
these events than Caucasians. Higher age at diagnosis is linked to a lower resolution 
rate. 
 
The association between NP states and health-related quality of life: Patient 
generated PCS and MCS scores associated with different NP states are summarized in 
Figure 4. There were clinically lower PCS and MCS scores in the new/ongoing NP state 
compared to the no NP and resolved NP states (global p-value<0.001). This was true 
for patient states, which could vary over time, defined by both SLE and non-SLE NP 
events. 
 
Discussion 
Heterogeneity of clinical manifestations, uncertainty in causal attribution, incomplete 
understanding of pathogenesis and few controlled clinical trials to guide treatment 
contribute to the challenge of NPSLE. Long-term studies of representative SLE cohorts 
provide information on the clinical course with current standard of care. A multistate 
modelling approach determined the frequency of NP events, their clinical outcomes and 
impact on HRQoL in an international prospective cohort of SLE patients. Estimates for 
occurrence and resolution of NP events over time in patients receiving standard of care 
provides a benchmark for clinical trials of new therapies. 
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The SLICC inception cohort has information on the occurrence and outcome of 
individual NP manifestations in addition to other SLE manifestations, comorbidities and 
treatment. Our study captures the totality of nervous system events and attribution over 
a mean follow-up of 7.6 years. Major organ manifestations of SLE frequently present 
early in the disease course, and thus a disease inception cohort is advantageous. 
Additional benefits include standardized, comprehensive assessments for NP events 
and centralized data driven decisions on attribution to SLE and non-SLE causes. The 
attribution of up to 30% of NP events to SLE in up to 20% of SLE patients is consistent 
with previous SLICC cohort studies(12, 23) and with other recent studies(3, 24).  
 
Multistate modelling has been applied to psoriatic arthritis(25, 26) lupus nephritis(27) 
and organ damage accrual in SLE(28) but has not previously been used to study 
NPSLE. Although NP events can present or recur at any time in the disease course, 
they are most frequent in the first few years following SLE diagnosis. This is the case for 
both NP events attributed to SLE and non-SLE causes, although the rate of recurrence 
compared to the rate for the initial event is higher for NP events attributed to SLE. As is 
the case with other SLE manifestations (27, 29), the occurrence of NP manifestations 
has implications for the subsequent disease course. Patients whose initial state was 
free of SLE NP events, had a 74% likelihood of being free of SLE NP events at 10 years 
of follow-up. For patients still free of SLE NP events two years after the diagnosis, this 
probability rises to 84%. Thus, if patients remain event free during this time, there is a 
high likelihood that NPSLE manifestations will not occur subsequently. For patients 
whose initial SLE NP state was “resolved”, or who subsequently had all NP events 
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resolve, there was a 72% probability of being free of SLE NP events after 10 years of 
follow-up. 
 
Individual types of NP events, regardless of attribution, are associated with reduced 
HRQoL(12, 15, 23) that is clinically and statistically significant. The current study found 
a similar association between NP events in total and reduced HRQoL that reverts 
towards normal with resolution of the events. More ominously, following 10 years of 
follow-up, there is a higher probability (16%) of death for patients who experience SLE 
NP events compared to those without SLE NP events (6%) with little increase 
associated with non-SLE NP events (7%).  Another recent large, long-term study(3) 
found that patients with NPSLE had a three-fold higher mortality with a hazard ratio 
(95% CI) of 3.09 (0.03-9.21). Thus, major organ involvement by SLE carries a higher 
mortality risk over time, although the cause of death is not necessarily attributed to 
affected organ systems(29).   
 
Transition rates between NP states were derived from clinically meaningful changes 
identified by treating physicians and supported by patient self-report health status. 
Potential applications of multistate modelling include using transition rates as a primary 
outcome in clinical trials and projecting the cost of care for NP disease. For example, 
the estimated probability of an SLE NP event resolving within 2 years is 0.31. A clinical 
trial to detect a 50% improvement in that rate would require a sample size (with an 
alpha level of 0.05 and 80% power) of 282 patients (141/group). Furthermore, by 
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determining the actual costs for each NP state and knowing the projected proportion of 
patients and the duration of time in each state, one can predict the costs of care. 
 
There are limitations to the current study. First although an inception cohort study is well 
suited to document NP events occurring early and likely due to active lupus, our study is 
not well positioned to detect NP events later in the disease course such as stroke and 
cognitive impairment from atherosclerosis and vascular dementia. Further follow-up will 
be required to address this. Second, SLICC is comprised predominantly of academic 
centres with a special interest in SLE that may not reflect community clinical practice. 
Third, as this is an observational study conducted in multiple international centers with 
annual study assessments there is potential for variability in data collection. Close 
communication between SLICC sites and operational rules for data collection and 
attribution have been implemented to keep this to a minimum. Finally, the complexity of 
a reversible multistate model to predict long-term probabilities of state occupancy, 
requires the use of parametric assumptions for transition rates, generally that the rate of 
transitioning out of a state is constant and does not depend on how long a patient has 
been in a state. 
 
Despite these limitations our study provides a comprehensive overview of NP events, 
their attribution and outcome in the first decade following the diagnosis of SLE in a 
representative group of SLE patients. Future studies will examine in detail the predictors 
of transition between the NP states and the economic costs associated with NPSLE. 
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Legends for figures 
 
Figure 1: Reversible multistate Markovian model for observed transitions in 
neuropsychiatric (NP) status in patients with SLE. 
 
Figure 2: Layered plot of trajectories of NP states recorded at study assessments, for 
all study patients, ordered sequentially at each assessment by NP states.  
 
Figure 3: Time from diagnosis of SLE to onset of new and recurrent SLE 
neuropsychiatric (NP) events (left panel) and for non-SLE neuropsychiatric events 
identified by attribution model B (right panel).  For recurrent events the time origin was 
the resolution of any previous event. The rate of recurrent SLE NP events occurred at a 
higher rate than first events with little difference in these rates for non-SLE events. 
 
Figure 4: SF-36 physical component (PCS) and mental component (MCS) summary 
scores (mean and 95% confidence interval) for patients in different neuropsychiatric 
(NP) states (global p-value<0.001). The SLE NP events and non-SLE NP events were 
determined using attribution model B. 
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